Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00657
|
|||||
| Drug Name |
Cholic acid
|
|||||
| Synonyms |
(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; 3,7,12-Trihydroxycholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; BHQCQFFYRZLCQQ-OELDTZBJSA-N; CHEBI:16359; CHEMBL205596; Cholalic acid; Cholalin; Cholic acid [USAN]; Cholic acid, 5beta-; Cholsaeure; Colalin; G1JO7801AE; HSDB 982; NSC-6135; NSC6135; UNII-G1JO7801AE; cholate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Peroxisomal disorders [ICD11:5C57.0] | Approved | [1] | |||
| Synthesis disorders [ICD11:5C52.10] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H40O5
|
|||||
| Canonical SMILES |
CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C
|
|||||
| InChI |
InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
|
|||||
| InChIKey |
BHQCQFFYRZLCQQ-OELDTZBJSA-N
|
|||||
| CAS Number |
CAS 81-25-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 408.6 | Topological Polar Surface Area | 98 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11110315
,14757556
,15277848
,17422064
,24423691
,24423929
,24892356
,24893153
,26717723
,26717726
,26717727
,26737120
,26737126
,26737128
,26750105
,26750407
,26750412
,26750415
,26750420
,26750424
,30424718
,3135999
,3963
,4266387
,46507063
,47193710
,47662491
,49700787
,50452100
,53787750
,53789207
,56313736
,56437567
,56437568
,57399957
,584143
,607109
,72129
,7886587
,81067251
,81091088
,8145669
,822057
,841391
,85279435
,85285851
,85285861
,85285865
,85285871
,9376190
|
|||||
| ChEBI ID |
CHEBI:16359
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASBT | Transporter Info | Apical sodium-dependent bile acid transporter | Substrate | [2] | |
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [5] | ||
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [6] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [7] | ||
| References | ||||||
| 1 | Cholic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69. | |||||
| 3 | Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83. | |||||
| 4 | Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75. | |||||
| 5 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 6 | Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82. | |||||
| 7 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.